
Devyser Diagnostics Q1 - The recognition of Devyser begins

Redeye sees a quarter well in line with our estimates, and we believe that the quarterly reports will push the share the remaining c30% to our current base case. We highlight that the gap to its peers' multiple valuations has shrunk after the strong share price development, but we argue that Devyser still trades too low compared to its cohort.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Devyser Diagnostics Q1 - The recognition of Devyser begins](#)